Related Experiment Videos
Symptomatic hypocalcemia after intravenous pamidronate
1Palliative Care Program, Edmonton General Hospital, Alberta, Canada.
Journal of Palliative Care
|January 1, 1996
Summary
A patient developed hypocalcemia after pamidronate treatment for metastatic renal/bladder cancer. This case highlights the need for careful monitoring of calcium levels, especially after hospital discharge.
Area of Science:
- Oncology
- Nephrology
- Endocrinology
Background:
- Metastatic renal and bladder carcinoma presents significant management challenges.
- Pamidronate is a bisphosphonate used in managing bone metastases and hypercalcemia of malignancy.
- Palliative care aims to improve quality of life for patients with serious illnesses.
Observation:
- A 65-year-old female patient with metastatic renal/bladder carcinoma was admitted for palliative care.
- The patient received a single dose of pamidronate.
- Nine days post-administration, the patient developed symptomatic hypocalcemia.
Findings:
- Symptomatic hypocalcemia occurred nine days after a single dose of pamidronate.
- The patient's underlying condition was metastatic renal/bladder carcinoma.
- The hypocalcemia was a complication potentially related to pamidronate treatment.
Implications:
- This case suggests a potential risk of delayed-onset hypocalcemia following pamidronate administration.
- Careful monitoring of serum calcium levels is crucial in patients treated with pamidronate, particularly those with renal impairment or malignancy.
- Consideration should be given to outpatient monitoring protocols for patients discharged after pamidronate treatment to prevent and manage hypocalcemia.